Introduction {#Sec1}
============

Cardiovascular disease (CVD) has been the leading cause of mortality in the United States of America (USA) every year since 1900, except 1918 (World War I) \[[@CR1]\]. Despite an almost 30% decrease in CVD-related mortality over the last decade, it remains the leading cause of mortality in the USA, accounting for over 1.4 million deaths annually. This equates to approximately 2200 deaths per day or 1 every 40 s. Globally, CVD accounts for over 17.3 million deaths or 31% of total global mortality \[[@CR2]\]. Current estimates state that 85.6 million people in the USA have some form of CVD, and by 2030, it is expected that approximately 44% of the US population will have CVD \[[@CR1]\]. Total direct and indirect costs of CVD in the USA are over \$316 billion annually and are expected to grow to over \$918 billion by 2030. Direct costs are mainly composed of hospital admissions, with over 69 million physician office visits and over 4.3 million emergency department visits annually \[[@CR1]\].

Much of the etiology of CVD is due to atherosclerosis and its thrombotic complications. Arterial beds most commonly impacted include the coronary, cerebral, and major peripheral arteries, including the renal, mesenteric, and lower extremity arteries. As atherosclerosis is a systemic disease, it rarely impacts a single arterial bed, even if symptoms have not developed \[[@CR3]\]. It is known that patients with a history of myocardial infarction (MI) are not only at risk of recurrent MI but also at higher risk of stroke than the general population \[[@CR3]--[@CR5]\]. Similarly, patients with a history of stroke are not only at a higher risk of recurrent stroke but also at a higher risk of MI than the general population \[[@CR3], [@CR6]\]. Patients with peripheral arterial disease (PAD) also have higher risk of MI and stroke than those without PAD \[[@CR3], [@CR7]\].

Due to the central role of platelets in the pathophysiology of arterial thrombosis, antiplatelet therapy is critical for the acute and chronic treatment of patients with atherosclerotic disease, regardless of the arterial bed impacted. In the coronary vasculature, dual antiplatelet therapy with clopidogrel and aspirin has been the standard of care in the management of patients with acute coronary syndrome (ACS) since the results of the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial in 2001 \[[@CR4], [@CR5], [@CR8]\]. In the cerebral and peripheral vascular beds, antiplatelet therapy has not advanced significantly beyond aspirin \[[@CR6], [@CR7]\].

The PARTHENON program, which was sponsored by AstraZeneca, is a series of completed and ongoing phase III clinical trials investigating the efficacy and safety of ticagrelor in atherosclerotic CVD in comparison with established antiplatelet therapy or placebo. The overall aim of the program is to determine if more potent antiplatelet therapy, with some different pharmacology, may reduce cardiovascular (CV) events in patients with atherosclerotic disease. The trials included in the PARTHENON program are listed in Table [1](#Tab1){ref-type="table"}.Table 1Clinical trials included in the PARTHENON programTrial acronymFull trial nameSize (*n*)Patient populationPLATOThe Study of Platelet Inhibition and Patient Outcomes18,624Acute coronary syndromePEGASUS--TIMI 54Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin--Thrombolysis in Myocardial Infarction 5421,162At least 1 year post-myocardial infarctionSOCRATESAcute Stroke or Transient Ischaemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes13,199Acute ischemic strokeEUCLIDExamining Use of tiCagreLor In paD13,885Peripheral artery diseaseTHEMISEffect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study\~ 19,000Type 2 diabetes mellitus with known coronary artery disease

Oral Antiplatelet Therapy {#Sec2}
=========================

Aspirin {#Sec3}
-------

Aspirin, or acetylsalicylic acid, provides its antiplatelet effect by irreversibly inhibiting platelet cyclooxygenase (COX). This is accomplished by aspirin acetylating a specific hydroxyl group of serine 530 on COX-1 enzyme, which inhibits the binding of arachidonic acid \[[@CR9]\]. Therefore, arachidonic acid cannot be converted to prostaglandin G~2~, which leads to reduced downstream production of thromboxane A2 \[[@CR10], [@CR11]\]. Aspirin has demonstrated benefit in reducing thrombotic events in patients with atherosclerosis, regardless of the vascular bed \[[@CR12]\]. Chronic low-dose aspirin (75 to 100 mg daily) has demonstrated similar efficacy and reduced bleeding compared with chronic higher-dose aspirin (200 to 325 mg daily) and is typically preferred for long-term therapy \[[@CR3], [@CR4], [@CR9], [@CR12], [@CR13]\].

P2Y~12~ Receptor Inhibitors {#Sec4}
===========================

Clopidogrel {#Sec5}
-----------

Clopidogrel is an orally administered, selective, irreversible inhibitor of the platelet P2Y~12~ receptor \[[@CR14], [@CR15]\]. Clopidogrel is a thienopyridine prodrug that requires a two-step hepatic activation via several cytochrome P450 (CYP) enzymes \[[@CR16]\]. While several CYP enzymes are involved in the conversion of clopidogrel to its active metabolite, the largest contributor is CYP2C19, which accounts for over 50% of active compound creation \[[@CR15], [@CR17]\]. The active metabolite of clopidogrel is responsible for binding to the P2Y~12~ receptor, which leads to platelet inhibition. The active metabolite of clopidogrel has a reactive thiol group, which forms a disulfide bridge with the cysteine residues on the P2Y~12~ receptor, creating an irreversible inhibition of the P2Y~12~ receptor for the life of the platelet \[[@CR18]\]. This ultimately leads to prevention of adenosine diphosphate (ADP)-mediated platelet activation and aggregation \[[@CR15], [@CR18]\].

Clopidogrel was initially evaluated in comparison to aspirin in the CAPRIE trial (Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events) \[[@CR19]\]. The CAPRIE trial included 19,185 patients with a history of stroke, MI, or PAD and followed for a mean of 1.9 years. While there was a significant 8.7% relative reduction with the use of clopidogrel over aspirin in the primary endpoint of MI, stroke, or vascular death, the absolute reduction was relatively small (5.3 vs. 5.8%; *P* = 0.043). Interestingly, patients enrolled with a history of PAD demonstrated the greatest benefit from clopidogrel over aspirin, with a 23.8% relative reduction in the primary endpoint (*P* = 0.003).

Clopidogrel in combination with aspirin was compared to aspirin alone in the CURE trial (*n* = 12,562) \[[@CR8]\]. In these patients with non-ST-elevation ACS, clopidogrel and aspirin significantly reduced the incidence of the primary endpoint of MI, stroke, or CV death compared to aspirin alone (9.3 vs. 11.4%; *P* \< 0.001). There was also an increase in major bleeding with dual antiplatelet therapy compared to aspirin alone (3.7 vs. 2.7%; *P* = 0.001). The results of the CURE trial created the basis for dual antiplatelet therapy to become the standard of care in patients with ACS.

Despite the widespread use of clopidogrel, there continues to be a significant rate of recurrent CV events \[[@CR8], [@CR20]\]. These events are potentially explained by issues related to clopidogrel, including variability in antiplatelet response in up to 40% of patients, pharmacogenomic influences, and drug interactions \[[@CR21]--[@CR24]\]. The prescribing information for clopidogrel was updated in 2016 to include a warning on the potential impact of CYP2C19 polymorphisms on clopidogrel pharmacokinetics and clinical response at the request of the US Food and Drug Administration (FDA) \[[@CR80]\]. While tests are available to identify a patient's CYP2C19 genotype, current treatment guidelines do not recommend routine testing for the polymorphism.

Prasugrel {#Sec6}
---------

Prasugrel, a third-generation P2Y~12~ receptor inhibitor, overcame a number of limitations of clopidogrel but has a similar thienopyridine chemical structure \[[@CR25]\]. Prasugrel is also a prodrug that requires hepatic conversion to its active compound, but this is a single step with multiple enzymes assisting in the conversion. Therefore, conversion of prasugrel to the active compound is much more efficient and successful compared with clopidogrel. Prasugrel also has a more rapid onset of action, a prolonged duration of antiplatelet effects, and a more consistent antiplatelet activity compared with clopidogrel \[[@CR26], [@CR27]\]. Prasugrel was compared to clopidogrel in patients with ACS undergoing percutaneous coronary intervention (PCI) in the TRITON--TIMI 38 trial (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel--Thrombolysis in Myocardial Infarction) \[[@CR28]\]. All patients (*n* = 13,608) also received aspirin. After approximately 12 months, patients receiving prasugrel demonstrated a significant reduction in the primary endpoint of MI, stroke, and CV mortality (9.9 vs. 12.1%; *P* \< 0.001). However, this was at the expense of significantly more non-coronary artery bypass grafting (CABG) major bleeding, life-threatening, and fatal bleeding. Bleeding was specifically higher in patients with a history of transient ischemic attacks (TIAs) or stroke, aged 75 years or older, or with a body weight \< 60 kg (132 lbs). Conversely, no differences in efficacy (MI, stroke, or CV death) or safety (major bleeding) were found between prasugrel and clopidogrel (with aspirin) when the agents were evaluated in ACS patients not treated with PCI in the TRILOGY ACS trial (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) \[[@CR29]\]. Data with prasugrel in other vascular beds are currently lacking.

Ticagrelor {#Sec7}
----------

Ticagrelor represents the first oral, direct-acting, reversible P2Y~12~ receptor inhibitor. Ticagrelor belongs to the chemical class of cyclopentyltriazolopyrimidines, which was developed from the chemical structure of a natural inhibitor of the P2Y~12~ receptor, adenosine triphosphate (ATP) \[[@CR30]\]. Compared with the thienopyridine P2Y~12~ inhibitors mentioned above, ticagrelor is not a prodrug and does not require hepatic activation prior to providing its antiplatelet activity, nor is it influenced by CYP2C19 genetic variants \[[@CR31]\]. This likely contributes to the lack of significant variability in antiplatelet activity, especially compared with clopidogrel. While the thienopyridines clopidogrel and prasugrel bind irreversibly to the P2Y~12~ receptor for the life of the platelet, ticagrelor has demonstrated both reversible and non-competitive binding to the P2Y~12~ receptor at a site that is different to that of the endogenous agonist ADP \[[@CR32]\]. Therefore, the antiplatelet effects of ticagrelor also dissipate more quickly than clopidogrel or prasugrel once the drug is discontinued, which may be associated with faster restoration of platelet function.

In addition to its antiplatelet effects, ticagrelor has also demonstrated the ability to increase adenosine concentrations. This most likely occurs through inhibition of the sodium-independent equilibrative nucleoside transporter 1 (ENT-1) \[[@CR33]--[@CR35]\]. Erythrocyte ENT-1 is responsible for uptake of adenosine into the cell, where it is metabolized by multiple mechanisms. The ability of ticagrelor to inhibit adenosine's uptake via ENT-1, and therefore increase adenosine's systemic exposure, is likely due to the similar chemical structure of the two molecules, since ticagrelor was developed through multiple chemical modifications of ATP \[[@CR35]\]. The quantifiable impact of the increased adenosine exposure is not fully understood but may provide clinical advantages and disadvantages to ticagrelor. Studies have demonstrated that ticagrelor can augment both endogenous and exogenous adenosine-induced coronary blood flow, which may provide a clinical advantage by producing improved perfusion in ischemic myocardium \[[@CR33], [@CR34]\]. Increased adenosine exposure may also explain some of the unique adverse effects observed with ticagrelor, (e.g., dyspnea, ventricular pauses, and gout) that are not typically seen with the thienopyridine P2Y~12~ inhibitors \[[@CR36], [@CR37]\].

Ticagrelor is rapidly absorbed, reaching peak concentrations in 2 to 3 h after multiple twice-daily dosing \[[@CR30]\]. Ticagrelor is principally metabolized via the CYP3A4 and 3A5 enzymes. The active metabolite of ticagrelor, AR-C124910XX, represents about one third of ticagrelor metabolism. The mean elimination half-life of ticagrelor and that of its active metabolite are approximately 6.7 to 9.1 h and 7.5 to 12.4 h, respectively. Renal elimination of ticagrelor and the active metabolite is minor and not impacted by changes in renal function \[[@CR30]\].

Numerous pharmacodynamic studies have demonstrated that ticagrelor provides rapid and potent platelet inhibition \[[@CR30]\]. Compared with patients receiving a 600-mg loading dose of clopidogrel, followed by 75 mg daily, a 180-mg loading dose of ticagrelor, followed by 90 mg twice daily, provided significantly faster and more potent inhibition of platelet aggregation (IPA) \[[@CR38]\]. Within 0.5 h, IPA with 20 μmol/L ADP was already significantly greater with ticagrelor compared with clopidogrel (41 vs. 8%; *P* \< 0.0001). By 2 h, IPA was 88% with ticagrelor compared with 38% with clopidogrel (*P* \< 0.0001) \[[@CR38]\]. Ticagrelor was also shown to provide significant platelet inhibition in patients who were not considered responders to clopidogrel \[[@CR39]\]. In a study of 41 clopidogrel non-responders, platelet aggregation dropped from 59% with clopidogrel down to 35% when these patients were switched to ticagrelor (*P* \< 0.001). These results show that ticagrelor provides more potent and faster platelet inhibition compared with clopidogrel, regardless of the patient response to clopidogrel \[[@CR39]\].

The PARTHENON Program {#Sec8}
=====================

Compared to thienopyridines, ticagrelor does not need hepatic activation, has a rapid onset of antiplatelet activity, potent platelet activity, consistent antiplatelet activity, reversible receptor binding, and a more rapid restoration of platelet function. Ticagrelor also has the potential to possibly improve coronary perfusion through increased adenosine exposure. Due to these pharmacologic advantages of ticagrelor over thienopyridines, a clinical trial program was developed to evaluate the role of ticagrelor in different types of atherosclerotic disease.

PLATO---Acute Coronary Syndrome {#Sec9}
-------------------------------

Dual antiplatelet therapy with aspirin and the P2Y~12~ receptor antagonist clopidogrel has demonstrated a significant benefit over aspirin alone in patients with non-ST-segment elevation (NSTE) ACS in the CURE trial in 2001 \[[@CR8]\]. Since these results, dual antiplatelet therapy has been considered standard of care for patients with ACS and has been incorporated into current treatment guidelines \[[@CR3]--[@CR5]\]. Despite the use of clopidogrel-based dual antiplatelet therapy, patients still have event rates of CV death, MI, or stroke of over 10% at 1 year \[[@CR8], [@CR28], [@CR40]\].

The PLATO trial represents the phase III clinical trial that evaluated the efficacy and safety of ticagrelor compared with clopidogrel in patients with ACS \[[@CR40]\]. Patients (*n* = 18,624) in the PLATO trial who presented within 24 h of an ACS event (NSTE ACS or ST-segment elevation MI \[STEMI\]) were randomized in a double-blinded fashion to a ticagrelor loading dose 180 mg, followed by 90 mg twice daily, or a clopidogrel loading dose of 300 or 600 mg, followed by 75 mg daily, for at least 6 and up to 12 months. All patients also received aspirin therapy dosed at the investigators' discretion. The primary efficacy end point of the trial was the composite of CV death, MI, and stroke.

There was a significant 16% relative reduction in the primary end point with the use of ticagrelor compared with clopidogrel (hazard ratio \[HR\] 0.84; 95% confidence interval \[CI\] 0.77--0.92) (Table [2](#Tab2){ref-type="table"}) \[[@CR40]\]. The benefit of ticagrelor over clopidogrel was evident within the first 30 days of treatment (4.8 vs. 5.4%; *P* = 0.045) and continued to increase from days 31 to 360 (5.3 vs. 6.6%; *P* \< 0.001). Therefore, the benefit demonstrated with ticagrelor in the PLATO trial was not just due to early potent antiplatelet therapy but also to maintained potent antiplatelet therapy. Definite stent thrombosis was also significantly reduced with the use of ticagrelor compared with clopidogrel in patients undergoing PCI with stenting (HR 0.67; 95% CI 0.50--0.91; *P* = 0.009) \[[@CR40]\].Table 2Efficacy and safety findings from the PLATO trial at 12 months \[[@CR40]\]Outcome (%)TicagrelorClopidogrelHR (95% CI)*P*-valueEfficacy Cardiovascular death, MI, or stroke9.811.70.84 (0.77--0.92)\<0.001 Cardiovascular death4.05.10.79 (0.69--0.91)0.001 MI5.86.90.84 (0.75--0.95)0.005 Stroke1.51.31.17 (0.91--1.52)0.22 Death from any cause4.55.90.78 (0.69--0.89)\<0.001 Stent thrombosis---definite1.31.90.67 (0.50--0.91)0.009 Stent thrombosis---definite or probable2.22.90.75 (0.59--0.95)0.02 Primary end point---invasive approach8.910.60.84 (0.75--0.94)0.003 Primary end point---ischemia-driven approachSafety PLATO total major bleeding11.611.21.04 (0.95--1.13)0.43 TIMI total major bleeding7.97.71.03 (0.93--1.15)0.57 PLATO non-CABG major bleeding4.53.81.19 (1.02--1.38)0.03 TIMI non-CABG major bleeding2.82.21.25 (1.03--1.53)0.03 Need for transfusion8.98.91.00 (0.91--1.11)0.96 Life-threatening bleeding5.85.81.03 (0.90--1.16)0.70 Intracranial bleeding0.30.21.87 (0.98--3.58)0.06 Fatal bleeding0.30.30.87 (0.48--1.59)0.66 PLATO major or minor bleeding16.114.61.11 (1.03--1.20)0.008 TIMI major or minor bleeding11.410.91.05 (0.96--1.15)0.33 Dyspnea---any13.87.81.84 (1.68--2.02)\<0.001 Dyspnea---requiring stopping study drug0.90.16.12 (3.41--11.01)\<0.001 Holter identified ventricular pauses ≥ 3 s at 7 days5.83.6NR0.01 Holter identified ventricular pauses ≥ 3 s at 30 days2.11.7NR0.52*CAGB* coronary artery bypass graft, *CI* confidence interval, *HR* hazard ratio, *MI* myocardial infarction; *NR* not reported; *PLATO* platelet inhibition and patient outcomes, *TIMI* thrombolysis in myocardial infarction

Of the individual components of the composite primary end point, MI was significantly reduced by 16% with the use of ticagrelor compared with clopidogrel (HR 0.84; 95% CI 0.75 to 0.95) \[[@CR40]\]. There was also a significant 21% reduction in the incidence of CV mortality (HR 0.79; 95% CI 0.69 to 0.91), which has rarely been demonstrated with an oral antiplatelet agent \[[@CR41], [@CR42]\]. It has yet to be determined if the reduction in CV death demonstrated with ticagrelor is due to its more potent antiplatelet effect compared with clopidogrel, improved adenosine-induced coronary perfusion, or both.

The benefit of ticagrelor over clopidogrel in reducing CV events in the PLATO trial was evident regardless of the management strategy. The magnitude of effect of ticagrelor was consistent between patients in whom an invasive strategy was planned (*n* = 13,408; HR 0.84; 95% CI 0.75 to 0.94) and those assigned to a non-invasive, ischemia-driven approach (*n* = 5216; HR 0.85; 95% CI 0.73 to 1.00) \[[@CR42], [@CR43]\]. The results were similar for the subgroup of patients undergoing primary PCI for STEMI (*n* = 7544; HR 0.87; 95% CI 0.75 to 1.01; *P* = 0.07), and in patients who underwent CABG surgery during the trial (planned or not) and who received their last dose of study drug within 7 days before surgery (*n* = 1899; HR 0.84; 95% CI 0.60 to 1.16; *P* = 0.29) \[[@CR44], [@CR45]\].

The chronic dose of aspirin was discovered to have an important influence on clinical outcome in the PLATO trial. In a subanalysis of the PLATO trial, the benefit of ticagrelor appeared to be attenuated in patients enrolled in North America, specifically the USA \[[@CR46]\]. Patients in the PLATO trial enrolled in the USA demonstrated a numerical increase in the primary end point with the use of ticagrelor compared with clopidogrel (11.9 vs. 9.5%; *P* = 0.1459), as well as each of the individual components of the composite end point. In further statistical analysis, it has been determined that this finding is likely due to the higher maintenance dose of aspirin used in the US compared with the rest of the world \[[@CR46]\]. Patients enrolled in the USA were more likely to take a median maintenance aspirin dose of ≥ 300 mg/day (53.6%) compared with the rest of the world (1.7%). Those patients who received a maintenance dose of aspirin of ≥ 300 mg/day in the USA had an increase in risk of CV events with the use of ticagrelor compared with clopidogrel (HR 1.62; 95% CI 0.99 to 2.64), but a reduction in CV events if the maintenance dose of aspirin was ≤ 100 mg (HR 0.73; 95% CI 0.40 to 1.33). It had also been discovered that the effect of aspirin dose on CV outcomes was not just a phenomenon revealed in the USA. Patients in the rest of world also demonstrated an impact of aspirin dose on CV outcomes, with patients receiving a lower maintenance dose of aspirin having benefit with ticagrelor compared with clopidogrel (HR 0.78; 95% CI 0.69 to 0.87) that seemed to be lost with a higher maintenance dose of aspirin (HR 1.23; 95% CI 0.71 to 2.14). Based on these data, maintenance doses of aspirin 75 to 100 mg daily are recommended in order for ticagrelor to demonstrate benefits over clopidogrel, and higher chronic aspirin doses are contraindicated \[[@CR47]\].

The incidence of total major bleeding using either the PLATO or Thrombolysis In Myocardial Infarction (TIMI) definition was not significantly increased with ticagrelor use compared with clopidogrel (Table [2](#Tab2){ref-type="table"}) \[[@CR40]\]. While total major bleeding was used as the primary safety end point in the PLATO trial, most antiplatelet therapy ACS trials use non-CABG major bleeding as the primary safety outcome due to the high rate of major bleeding seen in CABG surgery. When non-CABG major bleeding was evaluated, there was a significant increase for patients receiving ticagrelor compared with clopidogrel for PLATO major bleeding (HR 1.19; 95% CI 1.02 to 1.38; *P* = 0.03), as well as TIMI major bleeding (HR 1.25; 95% CI 1.03 to 1.16; *P* = 0.03). It should be noted that the incidences of life-threatening bleeding (5.8% in both groups) and fatal bleeding (0.3% in both groups) were not increased with the use of ticagrelor compared with clopidogrel \[[@CR40]\].

Based on the different chemical structure of ticagrelor compared with the traditional thienopyridine P2Y~12~ inhibitors, a number of unique side effects have been reported that have not been traditionally reported with the thienopyridine class of P2Y~12~ inhibitors (Table [2](#Tab2){ref-type="table"}) \[[@CR40]\]. In the PLATO trial, patients randomized to ticagrelor had a significantly higher rate of reported dyspnea compared with those randomized to clopidogrel (13.8 vs. 7.8%; *P* \< 0.001). Of the patients who reported dyspnea while receiving ticagrelor, 5.9% prematurely discontinued therapy compared with 1.6% of the clopidogrel patients who reported dyspnea (*P* \< 0.001). The overall discontinuation rate due to dyspnea was 0.9% for ticagrelor and 0.1% for clopidogrel (*P* \< 0.001). Most cases were judged to be mild to moderate in severity and occurred early in therapy, with resolution within 1 to 2 weeks of ticagrelor initiation \[[@CR48]\]. In the PLATO trial, there was no change in pulmonary function demonstrated in a subset of patients who underwent pulmonary function testing (*n* = 199) with ticagrelor or clopidogrel \[[@CR48]\]. Furthermore, patients with prior history of heart failure, chronic obstructive pulmonary disease, or other causes of dyspnea were not at higher risk of developing ticagrelor-related dyspnea.

Another side effect noted with the use of ticagrelor has been an increase in ventricular pauses of ≥ 3 s. In the 2908 patients in the PLATO trial who had a 7-day continuous electrocardiogram (ECG) recorder, pauses occurred in more patients receiving ticagrelor than clopidogrel (5.8 vs. 3.6%; *P* = 0.006) \[[@CR36], [@CR40]\]. At a follow-up ECG recording at 30 days, there was a similar proportion of patients with pauses (2.1 vs. 1.7%; *P* = 0.52). Most of the difference between the groups was in the incidence of sinoatrial node pauses. Importantly, there were no differences between the groups in the incidence of clinically reported bradycardia adverse events such as dizziness, syncope, pacemaker placement, or cardiac arrest \[[@CR40]\]. It should be noted that patients at increased risk of a bradycardic event (known sick sinus syndrome, second- or third-degree atrioventricular conduction block, or previously documented syncope suspected to be due to bradycardia unless treated with a pacemaker) were excluded from the PLATO trial.

PEGASUS--TIMI 54---Long-Term Dual Antiplatelet Therapy Following MI {#Sec10}
-------------------------------------------------------------------

The optimal duration of dual antiplatelet therapy has remained a question for many years. While studies have demonstrated the benefits of dual antiplatelet therapy for up to a year in patients with an ACS event, it has remained unknown if longer duration of dual antiplatelet therapy is beneficial \[[@CR8], [@CR28], [@CR40]\]. Of the coronary events that occur each year, approximately one third are recurrent events \[[@CR1]\]. In addition, registry data have demonstrated that the risk of recurrent events over a 4-year period is over 18% \[[@CR49]\]. Therefore, it is clear that patient risk of recurrent events is an ongoing concern. An initial study of dual antiplatelet therapy with clopidogrel plus low-dose aspirin was compared with low-dose aspirin alone in patients with a history of CVD or multiple risk factors for CVD \[[@CR50]\]. After 28 months of follow-up, clopidogrel-based dual antiplatelet therapy did not demonstrate a significant reduction in the primary end point of CV death, MI, or stroke compared with aspirin alone (6.8 vs. 7.3%; *P* = 0.22). However, a *post hoc* subgroup analysis in those patients with previous MI suggested a potential benefit in those receiving dual antiplatelet therapy \[[@CR51]\].

The PEGASUS--TIMI 54 trial specifically evaluated patients at least 1 year post-MI and utilized ticagrelor-based dual antiplatelet therapy compared with low-dose aspirin \[[@CR52]\]. In the trial, patients with a previous MI at least 1 year prior to study enrollment (*n* = 21,162) were randomized in a double-blinded fashion to ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo. All patients also received low-dose aspirin during the trial. The primary efficacy end point was the composite of CV death, MI, or stroke. The primary safety end point was TIMI major bleeding.

After a median follow up of 33 months, patients receiving ticagrelor 90 mg twice daily demonstrated a significant reduction in the rate of the primary end point compared with those receiving placebo (HR 0.85; 95% CI 0.75 to 0.96; *P* = 0.008) (Table [3](#Tab3){ref-type="table"}) \[[@CR52]\]. Patients receiving ticagrelor 60 mg twice daily also demonstrated a significant reduction in the rate of the primary end point compared with those receiving placebo, and at a similar degree of magnitude to the 90-mg dose (HR 0.84; 95% CI 0.74 to 0.95; *P* = 0.004). Interestingly, the magnitude of benefit was fairly consistent across all components of the primary end point. In patients randomized to ticagrelor 90 mg twice daily compared with placebo, the HR for CV death was 0.87 (*P* = 0.15), MI 0.81 (*P* = 0.01), and stroke 0.82 (*P* = 0.14). In patients randomized to ticagrelor 60 mg twice daily compared with placebo, the HR for CV death was 0.83 (*P* = 0.07), MI 0.84 (*P* = 0.03), and stroke 0.75 (*P* = 0.03). Therefore, the 60-mg dose of ticagrelor provided consistent efficacy over placebo compared with the 90-mg dose \[[@CR52]\].Table 3Efficacy and safety data from the PEGASUS--TIMI 54 trial \[[@CR52]\]Outcome (%)Ticagrelor 60 mg bidTicagrelor 90 mg bidPlaceboHR (95% CI) for 60 mg bid vs placebo*P*-valueHR (95% CI) for 90 mg bid vs placebo*P*-valueEfficacy CV death, MI, or stroke7.777.859.040.84 (0.74--0.96)0.0040.85 (0.75--0.96)0.008 CV death2.862.943.390.83 (0.68--1.01)0.070.87 (0.71--1.06)0.15 MI4.534.405.250.84 (0.72--0.98)0.030.81 (0.69--0.95)0.01 Stroke1.471.611.940.75 (0.57--0.98)0.030.82 (0.63--1.07)0.14 Death from any cause4.695.155.10.89 (0.76--1.04)0.141.00 (0.86--1.16)0.99Safety TIMI major bleeding2.302.601.062.32 (1.68--3.21)\<0.0012.69 (1.96--3.70)\<0.001 Intracranial hemorrhage0.610.560.471.33 (0.77--2.31)0.311.44 (0.83--2.49)0.19 Fatal bleeding0.250.110.261.00 (0.44--2.27)1.000.58 (0.22--1.54)0.27 Dyspnea---any15.8418.936.382.81 (2.50--3.17)\<0.0013.55 (3.16--3.98)\<0.001 Dyspnea---requiring stopping study drug4.556.500.796.60 (4.50--8.15)\<0.0018.89 (6.65--11.88)\<0.001 Renal events3.433.302.891.17 (0.94--1.45)0.151.17 (0.94--1.46)0.15 Bradyarrhythmia2.322.041.981.24 (0.96--1.61)0.101.15 (0.88--1.50)0.321 Gout1.972.281.511.48 (1.10--2.00)0.011.77 (1.32--2.37)\<0.001*bid* twice daily, *CI* confidence interval, *CV* cardiovascular, *HR* hazard ratio, *MI* myocardial infarction, *TIMI* thrombolysis in myocardial infarction

As might be expected with long-term exposure to dual antiplatelet therapy, in this trial, major bleeding was significantly increased with both ticagrelor 90 mg twice daily (HR 2.69; 95% CI 1.96 to 3.70; *P* \< 0.001) and ticagrelor 60 mg twice daily (HR 2.32; 95% CI 1.68 to 3.21; *P* \< 0.001) compared with placebo (Table [3](#Tab3){ref-type="table"}) \[[@CR52]\]. There was also significantly more TIMI minor bleeding and need for transfusion with either dose of ticagrelor when compared with placebo (Table [3](#Tab3){ref-type="table"}). Despite the increased incidence of major bleeding with the use of ticagrelor, rates of intracranial bleeding and fatal bleeding were not different compared with placebo. Similar to the PLATO trial, patients randomized to ticagrelor demonstrated significantly more dyspnea and dyspnea-related drug discontinuation compared with those who received placebo (Table [3](#Tab3){ref-type="table"}). While renal events and symptomatic bradycardia were not significantly different between the groups, there were more episodes of gout in patients randomized to either dose of ticagrelor. Based on the similar efficacy between the two doses of ticagrelor over placebo, and the numerically lower rates of bleeding and dyspnea with the lower dose of ticagrelor compared with the higher dose, ticagrelor 60 mg twice daily is the FDA-approved dose for patients who are at least 1 year post-MI \[[@CR47]\].

SOCRATES---Acute Stroke or TIA {#Sec11}
------------------------------

In the USA, approximately 6.6 million people have a history of a stroke or TIA \[[@CR1]\]. By 2030, this number is expected to grow by over 20% with an additional 3.4 million patients \[[@CR53]\]. Of the nearly 800,000 strokes that occur each year, 23% are recurrent events \[[@CR1]\]. Globally, 33 million people have a history of stroke or TIA, which accounts for 6.5 million deaths, or 11.8% of global mortality \[[@CR54], [@CR55]\]. Stroke is also the leading cause of long-term disability in the USA \[[@CR56], [@CR57]\]. After hospital discharge for stroke, less than half of patients go directly home, with the majority going to inpatient rehabilitation, a skilled nursing facility, or directly to a nursing home \[[@CR58]\]. These costs account for approximately \$33 billion annually \[[@CR58]\].

Optimal treatment of acute stroke includes intravenous or intra-arterial fibrinolysis \[[@CR59]\]. Unfortunately, most patients are not candidates for this therapy based on timing and other contraindications. Aspirin is the only other therapy proven to have a benefit in the treatment of acute stroke \[[@CR59]--[@CR61]\]. After initial therapy, antiplatelet therapy is currently recommended as the treatment of choice for prevention of further thrombotic events after an initial stroke or TIA \[[@CR6]\]. Recurrent ischemic stroke and other adverse vascular events occur in 10 to 20% of patients in the 3 months following TIA or minor ischemic stroke, with one study suggesting that 69% of strokes occurred within 7 days of a TIA \[[@CR51], [@CR62], [@CR63]\]. While dual antiplatelet therapy has not demonstrated a meaningful advancement in patients with ischemic stroke, the optimal choice of antiplatelet therapy remains unclear \[[@CR64]\].

The SOCRATES trial evaluated if the use of ticagrelor might provide a better reduction in vascular events compared with the only other evaluated oral therapy in patients with non-hemorrhagic acute ischemic stroke or TIA in the high-risk 3-month period following an event \[[@CR65]\]. Patients (*n* = 13,199) were randomized within 24 h of symptom onset in a double-blind, double-dummy fashion to ticagrelor 180 mg on day 1, followed by 90 mg twice daily, or aspirin 300 mg on day 1, followed by 100 mg once daily. Both therapies were continued through 90 days. Patients receiving fibrinolytic therapy for treatment of stroke were not included in the trial. The primary end point of the trial was the composite of stroke, MI, or death at 90 days.

Although there was an 11% reduction in the primary end point with the use of ticagrelor compared with aspirin in the SOCRATES trial, this difference did not achieve statistical significance (HR 0.89; 95% CI 0.78 to 1.01; *P* = 0.07) (Table [4](#Tab4){ref-type="table"}) \[[@CR65]\]. While there was no difference in the incidence of MI or CV death with the use of ticagrelor in this patient population, there was a reduction in the incidence of ischemic stroke (HR 0.87; 95% CI 0.76 to 1.00; *P* = 0.046) and all stroke (HR 0.86; 95% CI 0.75 to 0.99; *P* = 0.03) demonstrated with the use of ticagrelor compared with aspirin. Major bleeding, fatal bleeding, and intracranial bleeding were not increased with the use of ticagrelor compared with aspirin (Table [4](#Tab4){ref-type="table"}). While there was a numerical increase in the incidence of major or minor bleeding with the use of ticagrelor compared with aspirin, this difference did not achieve statistical significance (HR 1.32; 95% CI 0.99 to 1.76; *P* = 0.06) \[[@CR65]\].Table 4Efficacy and safety data from the SOCRATES trial \[[@CR65]\]Outcome (%)TicagrelorAspirinHR (95% CI)*P* valueEfficacy Death, MI, or stroke6.77.50.89 (0.78--1.01)0.07 CV death1.00.91.18 (0.83--1.67)0.36 MI0.40.31.20 (0.67--2.14)0.55 All stroke5.96.80.86 (0.75--0.99)0.03 Ischemic stroke5.86.70.87 (0.76--1.00)0.046 Fatal stroke0.30.30.90 (0.77--1.06)0.21Safety Major bleeding0.50.60.83 (0.52--1.34)0.45 Fatal bleeding0.10.1NRNR Intracranial hemorrhage0.20.30.68 (0.33--1.41)0.30 Major or minor bleeding1.61.21.32 (0.99--1.76)0.06*CI* confidence interval, *CV* cardiovascular, *HR* hazard ratio, *MI* myocardial infarction, *NR* not reported

EUCLID---Peripheral Artery Disease {#Sec12}
----------------------------------

Approximately 8.5 million patients in the USA live with PAD \[[@CR1]\]. Globally, this number grows to 202 million \[[@CR66]\]. Most mortality directly associated with PAD is associated with amputation, which has a 1-year mortality rate of over 48% \[[@CR67]\]. Patients with PAD in the USA also have significant resource utilization, with over 1.1 million physician office visits, 19,000 emergency department visits, and almost 300,000 hospital outpatient department visits \[[@CR1]\]. One of the main issues with PAD is the fact that it is a marker for systemic atherosclerosis. If patients have symptomatic atherosclerosis in the peripheral arterial bed, they are likely to have atherosclerotic disease in their coronary and/or cerebral arterial beds as well. Patients with PAD have rates of MI and stroke that are two- to four-fold higher than the general population, as well as higher rates compared with patients with only atherosclerotic risk factors, but not symptomatic disease \[[@CR7], [@CR49], [@CR68]\]. Another analysis also suggests higher rates of CV death, MI, or stroke in patients with PAD and an ACS event compared with those with an ACS event without PAD (19.3 vs. 10.2%; *P* \< 0.001), possibly due to patients with PAD representing a group with more extensive systemic atherosclerotic disease \[[@CR69]\].

Antiplatelet therapy with aspirin or clopidogrel is recommended for patients with PAD for prevention of CV death, MI, or stroke \[[@CR7]\]. This recommendation is for patients with symptomatic PAD, as well as those with an ankle-brachial index (ABI) ≤ 0.9 without symptoms. While many clinicians are likely to use aspirin therapy first, treatment with the P2Y~12~ inhibitor clopidogrel may be more effective. In the CAPRIE trial, patients with symptomatic coronary, cerebral, or peripheral atherosclerotic disease demonstrated a relative reduction of 8.7% in CV death, MI, or stroke with the use of clopidogrel compared with aspirin (*P* = 0.043) \[[@CR19]\]. Interestingly, this benefit was most profound (23.8%; *P* = 0.0028) in patients with PAD. Therefore, P2Y~12~ inhibitor therapy may be especially beneficial in this patient population.

Since clopidogrel may be considered optimal antiplatelet therapy for patients with PAD, the EUCLID trial evaluated if more potent P2Y~12~ inhibitor therapy with ticagrelor may reduce clinical outcomes compared with clopidogrel \[[@CR70]\]. Patients (*n* = 13,885) in the EUCLID trial had symptomatic PAD defined as symptoms with an ABI ≤ 0.80 or prior lower extremity revascularization for symptomatic PAD at least 30 days ago \[[@CR71]\]. Patients were randomized in a double-blinded fashion to clopidogrel 75 mg daily or ticagrelor 90 mg twice daily. The primary end point was the composite of CV death, MI, or ischemic stroke after 30 months of follow-up. The primary safety end point was TIMI major bleeding.

The results of the EUCLID trial demonstrated that there was no difference in the primary composite end point after a mean of 30 months of treatment with ticagrelor compared with clopidogrel (HR 1.02; 95% CI 0.92 to 1.13) (Table [5](#Tab5){ref-type="table"}). While there was also no difference between the individual end points of CV death or MI, there was a significant reduction in the incidence of ischemic stroke with the use of ticagrelor compared with clopidogrel (HR 0.78; 95% CI 0.62 to 0.98) (Table [5](#Tab5){ref-type="table"}). Other secondary outcomes such as hospitalization for acute limb ischemia or the need for lower-limb revascularization were also not different between the groups (Table [5](#Tab5){ref-type="table"}). Interestingly, patients with a known history of coronary or carotid revascularization (*n* = 3815) and those with a history of stent implantation (*n* = 1968) did respond differently compared with those without these more advanced atherosclerotic disease features (*P* value for interaction 0.03 for both). Major TIMI bleeding was similar between the groups (HR 1.10; 95% CI 0.84 to 1.43), as well as intracranial, fatal, or TIMI minor bleeding (Table [5](#Tab5){ref-type="table"}). There were higher rates of any bleeding and dyspnea with the use of ticagrelor compared with clopidogrel (Table [5](#Tab5){ref-type="table"}).Table 5Efficacy and safety data from the EUCLID trial \[[@CR71]\]Outcome (%)TicagrelorClopidogrelHR (95% CI)*P* valueEfficacy CV death, MI, or ischemic stroke10.810.61.02 (0.92--1.13)0.65 CV death5.24.91.07 (0.92--1.23)0.40 MI5.04.81.06 (0.91--1.23)0.48 Ischemic stroke1.92.40.78 (0.62--0.98)0.03 Death from any cause9.19.10.99 (0.89--1.11) Hospitalization for acute limb ischemia1.71.71.03 (0.79--1.33)0.85 Lower-limb revascularization12.212.80.95 (0.87--1.05)0.30Safety TIMI major bleeding1.61.61.10 (0.84--1.43)0.49 Intracranial bleeding0.50.51.06 (0.66--1.70)0.82 Fatal bleeding0.10.30.53 (0.25--1.13)0.10 TIMI minor bleeding1.21.01.32 (0.96--1.83)0.09 Dyspnea4.80.8NR\<0.001 Any bleeding2.41.6NR\<0.001*CI* confidence interval, *CV* cardiovascular, *HR* hazard ratio, *MI* myocardial infarction, *TIMI* thrombolysis in myocardial infarction, *NR* not reported

THEMIS---Type 2 Diabetes Mellitus {#Sec13}
---------------------------------

Approximately 21.1 million adults in the USA have the diagnosis of diabetes mellitus (DM), with an estimated 8.1 million undiagnosed and over 80 million with prediabetes \[[@CR1]\]. Type 2 DM (T2DM) accounts for 90 to 95% of all cases of DM in adults. Patients with T2DM have a two- to four-fold increase in risk of CVD compared with patients without DM \[[@CR72], [@CR73]\]. Furthermore, following MI, patients with DM have rates of mortality and recurrent events comparable to those without T2DM \[[@CR74]\]. Current recommendations include the use of aspirin for primary prevention of CV events for patients with DM \[[@CR75]\]. It has been well documented that patients with T2DM have higher platelet reactivity and a blunted response to aspirin. While the exact mechanism is unknown, it may be due to hyperglycemic-specific contributions such as COX-1 glycation and platelet insulin resistance \[[@CR76]\]. In the PLATO trial, ticagrelor provided a consistent benefit over clopidogrel, regardless of whether patients did or did not have DM \[[@CR77]\]. Ticagrelor has also demonstrated the ability to achieve better platelet inhibition compared with prasugrel in patients with DM with an ACS undergoing PCI \[[@CR78]\].

The THEMIS trial (NCT01991795) is designed to evaluate the efficacy and safety of ticagrelor in patients aged 50 years or more with T2DM with known coronary artery disease (*n* \~ 19,000) but without a history of an MI or stroke \[[@CR79]\]. Patients will be randomized to ticagrelor 60 mg twice daily or placebo in a double-blinded fashion. The primary end point will be the composite of CV death, MI, or stroke at 48 months. Results of the THEMIS trial are expected in late 2018 or early 2019.

Conclusion {#Sec14}
==========

The PARTHENON trials to date have demonstrated superiority of ticagrelor in some trials and a neutral impact in others. The reason for these mixed results could comprise a number of factors, including the disease state or vascular bed evaluated, duration of follow-up, or the comparator agent. In the PLATO trial, ticagrelor demonstrated superiority to clopidogrel as part of dual antiplatelet therapy. These positive effects are likely due to the improved antiplatelet response and duration of therapy of 6 months to a year. The high-risk nature of patients with ACS also likely contributed to the separation in event rates. The potential increase in coronary perfusion from increased adenosine exposure also could have contributed to the reduced CV mortality in the acute setting. In the PEGASUS trial, there was also a superiority effect of ticagrelor and aspirin over aspirin alone. The absolute benefit was not as great as that demonstrated in the PLATO trial. Since most patients were almost 2 years from their index MI, these were not acute patients and had more stable disease. Therefore, the benefit of more potent antiplatelet effect was evident, but the acute benefit of potential improved coronary perfusion was likely absent.

In the SOCRATES trial, ticagrelor was neutral compared to aspirin in impacting the primary endpoint of stroke, MI, and death at 90 days. The 90-day time frame is the period for the highest rate for recurrent stroke in acute stroke trials. While ticagrelor did significantly reduce recurrent stroke at 90 days, this is not likely sufficient follow-up for reducing MI or CV death in patients without symptomatic cardiac disease. Therefore, the composite endpoint was not well matched for a 90-day endpoint. Approximately one third of patients were already taking aspirin at the time of their acute stroke. Therefore, these patients may already have a lack of response to antiplatelet therapy and/or a non-ischemic etiology that resembles a TIA. Ticagrelor also demonstrated a neutral effect compared to clopidogrel in the EUCLID trial. While patients with PAD do have MI, stroke, and CV death, it is not as acute a risk as in the setting of ACS. Only 29% of patients had a history of coronary artery disease. Since the comparison was clopidogrel instead of aspirin, the ability of the more potent antiplatelet therapy with ticagrelor may not have been able to produce a reduction in events in this lower-risk patient population. As mentioned previously, patients with a history of coronary or carotid revascularization, and those with stent implantation, responded more favorably to ticagrelor compared to clopidogrel.

Atherosclerosis is a systemic disease impacting mainly the coronary, cerebral, and major peripheral arteries. The thrombotic nature of this disease contributes to significant morbidity and mortality. While antiplatelet therapies are often employed for the treatment and prevention of CV events in these patients, the optimal therapy in each vascular bed remains unknown. The PARTHENON program is a broad clinical development program that is ongoing and will continue to test ticagrelor across a wide spectrum of patients with atherosclerosis. These studies will inform clinical practice on the role of ticagrelor in these patients. As with any antiplatelet therapy, these benefits must be weighed against adverse effects such as bleeding and dyspnea.
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